ArticleCell reports. Medicine2025
Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting.
Abstract read
In one paragraph
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Emerging strategies and innovations in circular RNA synthesis.Molecular therapy. Nucleic acids · 2026Review
- Nucleoside-modified circRNA: Reduced immunogenicity and expansive applications beyond vaccines.Molecular therapy. Nucleic acids · 2026Article
- Chimeric antigen receptor-macrophages: A new paradigm for cell therapy.Bioengineering & translational medicine · 2026Review
- Cancer Vaccine Development: Toward Artificial Intelligence-Assisted Personalized Cell Membrane Nanovaccine.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Antimicrobial Peptide BSN-37 Enhances Macrophage Immune Activation Through the circBptf-Rbm14-Mediated Regulatory Axis.Probiotics and antimicrobial proteins · 2026Article
- Review
- Engineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer.Nature biomedical engineering · 2026Article
- In vivo CAR-M therapy: advancing precision delivery and programmable immune remodeling.Cell communication and signaling : CCS · 2026Review
- The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects.Signal transduction and targeted therapy · 2026Review
- Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases.Journal of hematology & oncology · 2026Review
- Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies.Journal of hematology & oncology · 2026Review
- Lipid nanoparticle delivery of circle RNA vaccine induces potent immune responses.Scientific reports · 2026Article
- Self-amplifying RNA-based CAR T cell therapy with enhanced duration and multi-genic logic functions.bioRxiv : the preprint server for biology · 2026Article
- Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma.Signal transduction and targeted therapy · 2026Article
- Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives.Vaccines · 2026Review
- CAR-macrophages: a new chapter in cancer immunotherapy.Acta biochimica et biophysica Sinica · 2026Article
- Circular RNAs: key regulators in cancer stem cell dynamics.Molecular genetics and genomics : MGG · 2026Review
- Review
- In vivo engineering of CAR-T cells: delivery strategies and clinical translation.Biomarker research · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Yanyan WangFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China.
Liangru LinBeijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing 101400, China; School of Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing 100049, China; Huairou Laboratory, Beijing 101400, China.
Xinyue WangFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China.
Jing LiFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China.
Qian PanFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China.
Haomeng KouFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China.
Jie YinFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China.
Fei GaoFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China.
Xinyuan LiaoFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China.
Chenchen ZhangHuman Phenome Institute, Fudan University, Shanghai 200032, China.
Qimeng YinHuman Phenome Institute, Fudan University, Shanghai 200032, China.
Chengzhi ZhaoSchool of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Xinyang LiFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China.
Jinzhong LinState Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China.
Yichi XuFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China. Electronic address: xuyichi@fudan.edu.cn.
Min QiuHuman Phenome Institute, Fudan University, Shanghai 200032, China. Electronic address: mqiu@fudan.edu.cn.
Dan LuoBeijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing 101400, China; School of Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address: luodan@binn.cas.cn.
Liang QuFrontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Zhongshan Hospital Clinical Center for Biotherapy, Fudan University, Shanghai 200032, China. Electronic address: quliang@fudan.edu.cn.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) T cell therapy has shown promise in treating hematologic malignancies, but it still faces challenges, including high costs, a time-consuming manufacturing process, and the necessity of lymphodepletion. Here, we generate circular RNAs (circRNAs) encoding CAR proteins, referred to as circRNA
Indexed as
Cancer VaccinesReceptors, Chimeric AntigenRNA, CircularAnimalsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunotherapyImmunotherapy, AdoptiveKiller Cells, NaturalMacrophagesMiceMice, Inbred BALB CMice, Inbred C57BLNanoparticlesCancer VaccinesErb-b2 Receptor Tyrosine KinasesReceptors, Chimeric AntigenRNA, CircularcircRNA vaccinein vivo CARoff-the-shelf CARpanCAR immunotherapyRNA therapeutics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.